Nothing Special   »   [go: up one dir, main page]

Keski-Oja et al., 1988 - Google Patents

Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta

Keski-Oja et al., 1988

View PDF
Document ID
13733068829131602993
Author
Keski-Oja J
Blasi F
Leof E
Moses H
Publication year
Publication venue
The Journal of cell biology

External Links

Snippet

Transforming growth factor-beta (TGF beta) is a regulator of cellular proliferation which can alter the proteolytic activity of cultured cells by enhancing the secretion of endothelial type plasminogen activator inhibitor and affecting the secretion of plasminogen activators (PAs) …
Continue reading at europepmc.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Similar Documents

Publication Publication Date Title
Keski-Oja et al. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta
Laiho et al. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta.
Lund et al. Transforming growth factor‐beta is a strong and fast acting positive regulator of the level of type‐1 plasminogen activator inhibitor mRNA in WI‐38 human lung fibroblasts.
Saksela et al. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.
Mignatti et al. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor.
Unemori et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
Koivunen et al. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor‐associated trypsinogen
Blei et al. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis
Keski-Oja et al. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells.
Masure et al. Purification and identification of 91‐kDa neutrophil gelatinase: Release by the activating peptide interleukin‐8
Danø et al. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion
Laiho et al. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase.
Saksela et al. Urokinase‐type plasminogen activator and its inhibitor secreted by cultured human monocyte‐macrophages
Odekon et al. Urokinase‐type plasminogen activator mediates basic fibroblast growth factor‐induced bovine endothelial cell migration independent of its proteolytic activity
Pepper et al. Upregulation of urokinase receptor expression on migrating endothelial cells
Lund et al. Urokinase‐receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.
Kahaleh Endothelin, an endothelial‐dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action
Koivunen et al. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix
Quax et al. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
Stoppelli et al. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
Kurdowska et al. Acute phase protein stimulation by alpha 1-antichymotrypsin-cathepsin G complexes. Evidence for the involvement of interleukin-6.
Albo et al. Thrombospondin-1 and transforming growth factor-betal promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system
Andreasen et al. Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells
Hollas et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines
Gerwin et al. TGF-beta 1 modulation of urokinase and PAI-1 expression in human bronchial epithelial cells